Research programme: DNA-based monoclonal antibodies - infections - Inovio/MedImmune/University of Pennsylvania

Drug Profile

Research programme: DNA-based monoclonal antibodies - infections - Inovio/MedImmune/University of Pennsylvania

Latest Information Update: 27 Oct 2014

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals; MedImmune; University of Pennsylvania
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections; Pseudomonal infections; Staphylococcal infections

Most Recent Events

  • 21 Oct 2014 Preclinical trials in Staphylococcal infections in USA (Intradermal)
  • 21 Oct 2014 Preclinical trials in Pseudomonal infections in USA (Intradermal)
  • 21 Oct 2014 Preclinical trials in Influenza virus infections in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top